Gregory selected to 10x Genomics CTRN

By Beth Rusnak, Duke Molecular Physiology Institute

The Molecular Genomics Core of Simon Gregory, PhD, was among the first 45 international members selected for participation in 10x Genomics Visium Clinical Translational Research Network (CTRN). The first members were selected from 185 total applications and represent a diverse range of studies that are taking place around the world. Members are focused on research in oncology, immuno-oncology, neuroscience, infectious disease, inflammation and fibrosis, COVID-19, including Dr. Gregory’s Alzheimer Research, done in collaboration with Dianne Cruz, MS (Duke Psychiatry) and Shih-Hsiu (Jerry) Wang, MD, PhD (Duke Pathology)

The 10x Genomics Visium CTRN was established to improve and accelerate workflows related to assessing the spatial cellular relationship in clinical translational research studies. Visium has the potential to aid in many clinical translational research applications, including biomarker and drug target discovery, engineered immune cell therapy and clinical trial development.

Members gain exclusive access to a collaborative, global research community dedicated to accelerating clinical translational research workflows, as well as substantial discounts and specialized support relating to the 10x Genomics Visium platform.

The 10x Genomics CTRN Spatial Summit, the details of which are expected to be revealed later this year, will feature talks by various members. Gregory will present his research at the Summit.

A version of this story originally appeared on the website of the Duke Molecular Physiology Institute. Read that article here.

Share